News and reporting on cell-free DNA testing.
Researchers published the most comprehensive data to date showing that Grail's screening approach can detect and distinguish a significant number of cancers.
The approach, called Lung-CLiP, couples machine learning trained on epigenetic and clonal frequency data with the detection of alterations in blood-borne DNA.
The drug, tepotinib, will now be available to treat advanced non-small cell lung cancer patients in Japan with MET exon 15 skipping alterations.
The company began offering testing to clinicians in the first quarter of this year and expects volume to grow significantly over the next several months.
The company announced an agreement with Piper Sandler & Co. to act as agent, creating an at-the-market equity program for up to $25 million in shares of its common stock.
